Inari Medical to Announce Third Quarter 2022 Financial Results
Inari Medical, Inc. (NASDAQ: NARI) plans to release its third quarter 2022 financial results on November 2, 2022. The medical device company, focused on treating venous diseases, will host a conference call at 1:30 p.m. PT to discuss its results and recent highlights. Inari's product line includes the ClotTriever and FlowTriever systems, designed for the non-surgical removal of clots from large vessels, addressing conditions like deep vein thrombosis and pulmonary embolism. Interested parties can access the call via telephone or through their investor relations website.
- Upcoming release of Q3 2022 financial results may indicate financial health.
- Strong focus on innovative medical devices for venous disease treatment.
- None.
IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its Q3 2022 financial results?
What time is the earnings call for Inari Medical's Q3 2022 results?
How can I access the Inari Medical earnings call?
What products does Inari Medical offer for treating venous diseases?
